Stocks
NeoGenomics Projects $797M-$803M 2026 Revenue
NeoGenomics forecasts significant revenue growth for 2026, projecting between $797 million and $803 million, boosted by the PanTracer Liquid MolDX approval.
#healthcare 3 articles
Markets
Eli Lilly’s Diversification Offers Stronger Investment Case
Beyond its weight-loss drug success, Eli Lilly's robust pipeline across oncology, immunology, and neuroscience presents a compelling investment thesis.
Stocks
Enveric Biosciences Secures Up to $13.9 Million in Private Placement
Enveric Biosciences announced a private placement expected to raise up to $13.9 million, with $5 million upfront and potential additional proceeds from...